Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and Financial Reports - Analyst Notes on Arrowhead,

 Regulatory Approvals, Pricing of Public Offering, Stock Price Movements, and
   Financial Reports - Analyst Notes on Arrowhead, ANI, OraSure, Rigel, and
                             Foundation Medicine

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, March 10, 2014

NEW YORK, March 10, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Arrowhead
Research Corp. (NASDAQ: ARWR), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP),
OraSure Technologies, Inc. (NASDAQ: OSUR), Rigel Pharmaceuticals, Inc.
(NASDAQ: RIGL), and Foundation Medicine, Inc. (NASDAQ: FMI). Private wealth
members receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register

Arrowhead Research Corp. Analyst Notes

On March 3, 2014, Arrowhead Research Corp. (Arrowhead) announced that it has
received a regulatory approval to initiate a Phase 2a clinical trial of
ARC-520, its RNAi-based drug candidate for the treatment of chronic hepatitis
B virus (HBV) infection. According to Arrowhead, the Hong Kong Department of
Health issued a Certificate for Clinical Trial that allows the Company to
proceed with its planned single-dose study of ARC-520 in two cohorts at two
dose levels to be conducted at Queen Mary Hospital and Prince of Wales
Hospital in Hong Kong. Arrowhead reported that the site initiation was
completed and patient screening will begin shortly. The Company added that the
topline study results are expected to be available in Q3 2014. The full
analyst notes on Arrowhead Research Corp. are available to download free of
charge at:

http://www.AnalystsReview.com/03102014/ARWR/report.pdf

ANI Pharmaceuticals, Inc. Analyst Notes

On March 5, 2014, ANI Pharmaceuticals, Inc. (ANI) announced the pricing of a
firm commitment underwritten public offering of 1,402,525 shares of the
Company's common stock at a purchase price to the public of $31.00 per share.
ANI reported that net proceeds to the Company are estimated to be $43.5
million, before estimated offering expenses payable by the Company. ANI added
that the offering is expected to close on or about March 10, 2014, and it has
granted the underwriters a 30-day option to purchase up to an additional
210,378 shares. The Company stated that it anticipates utilizing the net
proceeds of the offering to research, develop, commercialize, and expand its
drug products, to acquire complementary businesses and technologies, and for
working capital and general corporate purposes. The full analyst notes on ANI
Pharmaceuticals, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03102014/ANIP/report.pdf

OraSure Technologies, Inc. Analyst Notes

On March 5, 2014, OraSure Technologies, Inc.'s (OraSure) stock advanced
11.37%, ending the day at $8.23. Over the previous three trading sessions,
shares of OraSure climbed 18.58%, compared to the Nasdaq Composite which
increased 1.16% during the same period. The full analyst notes on OraSure
Technologies, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03102014/OSUR/report.pdf

Rigel Pharmaceuticals, Inc. Analyst Notes

On March 4, 2014, Rigel Pharmaceuticals, Inc. (Rigel) released its Q4 2013 and
full-year 2013 results. Rigel registered quarterly revenues of $5.8 million in
Q4 2013, with no comparable revenues in Q4 2012, while annual revenues were
$7.2 million in full year 2013, compared to $2.3 million in full year 2012.
The Company posted quarterly net loss of $16.9 million or $0.19 per diluted
share, compared to net loss of $25.5 million or $0.30 per diluted share in Q4
2012; while annual net loss came in at $89.0 million or $1.02 per diluted
share, compared to net loss of $98.8 million or $1.32 per diluted share in
full year 2012. James M. Gower, Rigel Chairman and CEO, said, "As 2014
unfolds, Rigel has a number of significant clinical research projects in the
works, which include a good combination of more advanced projects, such as
fostamatinib in ITP, and earlier ones, such as R118 in intermittent
claudication." Gower added, "We look forward to initiating the first of our
two pivotal P3 trials of fostamatinib in ITP next month." The full analyst
notes on Rigel Pharmaceuticals, Inc. are available to download free of charge
at:

http://www.AnalystsReview.com/03102014/RIGL/report.pdf

Foundation Medicine, Inc. Analyst Notes

On March 5, 2014, Foundation Medicine, Inc.'s (Foundation Medicine) stock
closed at $35.53, up 7.76%. Over the previous three trading sessions,
Foundation Medicine's shares fell 0.28%, compared to the Nasdaq Composite
which rose 1.16% during the same period. The full analyst notes on Foundation
Medicine, Inc. are available to download free of charge at:

http://www.AnalystsReview.com/03102014/FMI/report.pdf

About Analysts Review

We provide our members with a simple and reliable way to leverage our economy
of scale. Most investors do not have time to track all publicly traded
companies, much less perform an in-depth review and analysis of the
complexities contained in each situation. That's where Analysts Review comes
in. We provide a single unified platform for investors' to hear about what
matters. Situation alerts, moving events, and upcoming opportunities.

EDITOR NOTES:

  oThis is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
  oInformation in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
  oThis information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
  oIf you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at pubco [at]
    AnalystsReview.com.
  oFor any urgent concerns or inquiries, please contact us at compliance [at]
    AnalystsReview.com.
  oAre you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to research [at]
    AnalystsReview.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Analysts Review. An
outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Analysts Review in this article or
report according to the Procedures outlined by Analysts Review. Analysts
Review is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Analysts Review makes no warranty, expressed or implied, as to the accuracy or
completeness or fitness for a purpose (investment or otherwise), of the
information provided in this document. This information is not to be construed
as personal financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold any
securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Analysts Review is not responsible for any error which may be occasioned at
the time of printing of this document or any error, mistake or shortcoming. No
liability is accepted by Analysts Review whatsoever for any direct, indirect
or consequential loss arising from the use of this document. Analysts Review
expressly disclaims any fiduciary responsibility or liability for any
consequences, financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1) guarantee the
accuracy, timeliness, completeness or correct sequencing of the information,
or (2) warrant any results from use of the information. The included
information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts Review

Contact: CONTACT PERSON: Adam Redford CONTACT PHONE: +852-8191-3972
 
Press spacebar to pause and continue. Press esc to stop.